Evidence-based articles for the informed patient and caregiver - bridging the gap between PubMed abstracts and actionable knowledge. No false hope, no despair. Clear-eyed precision.
A post-treatment MRI showing new or enlarged areas of enhancement does not automatically mean the tumor is growing. Pseudoprogression - a treatment-related imaging change that mimics progression on standard MRI - affects a meaningful proportion of glioblastoma patients after chemoradiation, and identifying it correctly shapes every clinical decision that follows.
A second opinion is not a delay - it is due diligence. Here is exactly what to collect, what to ask, and how to compare two treatment plans when they differ.
Glioblastoma clinical trials offer access to experimental treatments not yet available as standard care, but only a small fraction of patients ever enroll. This guide explains how trials are structured, where to find open ones, what determines eligibility, and what to ask before signing the consent form.
Before traveling abroad for glioblastoma surgery, know which credentials to verify, which questions to ask, and what outcome data to request from the center. A practical framework for international families and caregivers making this decision under pressure.
Venous thromboembolism - blood clots in deep veins or the lungs - affects up to 39 percent of glioblastoma patients during treatment. This guide explains why the risk is so high and what care teams do to manage it.
Diffuse midline glioma is a WHO grade 4 brain or spinal cord tumor defined by an H3K27 molecular alteration. This guide explains what the pathology report means, how treatment is approached, and where to find a specialist with real experience treating this rare tumor.
Returning to work after glioblastoma is possible for some patients, but it requires an honest assessment of cognitive function, fatigue, seizure control, and job demands. This guide covers the most common barriers and how to build a realistic return-to-work plan with your care team.
Radiation for glioblastoma can be delivered over six weeks or compressed into three. This article explains how the two schedules compare, who each suits, and what major clinical trials show about survival outcomes.
Cannabinoids show consistent anti-tumor effects in GBM laboratory models, and early human trials have produced signals worth watching. This article explains the current trial landscape, what THC and CBD may and may not do, and the legal status of medical cannabis in countries across the GCC, Africa, India, the UK, and beyond.
First glioblastoma recurrence brings a complex, less standardized treatment landscape. Learn how to build a strong second opinion file, how re-irradiation, laser ablation, and clinical trials compare, and what to ask before committing to any salvage plan.